Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Parallel-Group, Cluster-Randomized Controlled Trial Evaluating an Artificial Intelligence Clinical Decision Support System for Selection of First-Line Immune Checkpoint Inhibitor-Based Therapy in Unresectable Hepatocellular Carcinoma

NCT07729618 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT07729618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07729618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Parallel-Group, Cluster-Randomized Controlled Trial Evaluating an Artificial Intelligence Clinical Decision Support System for Selection of First-Line Immune Checkpoint Inhibitor-Based Therapy in Unresectable Hepatocellular Carcinoma
Lead sponsor
Tongji Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
December 1, 2029
Enrollment
1,800 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable hepatocellular carcinoma